Another bispecific, humanized IgG1 antibody that is definitely below investigation is zenocutuzumab (MCLA-128), which acts by using two independent mechanisms of action: inhibition of HER2–HER3 signalling and elimination of tumour cells by using ADCC. MCLA-128 capabilities by using a ‘dock and block’ mechanism whereby just one arm from the antibody https://www.directivepublications.org/journal-of-clinical-breast-cancer/